Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BTX 1503 dose-finding study in moderate to severe facial acne vulgaris
ACTRN12618001047280Phase 2Completed
- Sponsor
- Botanix Pharmaceuticals
- Start
- Jun 2018
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 2
01
Overview
A Phase 2 trial of BTX 1503 in acne vulgaris, sponsored by Botanix Pharmaceuticals. Started Jun 2018; status: completed.
02
Drugs
BTX 1503
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on ACTRN12618001047280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001047280.